Download PDF
Nuklearmedizin
DOI: 10.1055/a-2512-8212
Original Article

Radiomic signatures derived from baseline 18F FDG PET/CT imaging can predict tumor-infiltrating lymphocyte values in patients with primary breast cancer

Radiomische Signaturen, die aus der Baseline-18F-FDG-PET/CT-Bildgebung abgeleitet werden, können tumorinfiltrierende Lymphozytenwerte bei Patienten mit primärem Brustkrebs vorhersagen
Özge Vural Topuz
1   Department of Nuclear Medicine, Başakşehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey (Ringgold ID: RIN622463)
,
Sidar Bağbudar
2   Department of Pathology, Başakşehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey (Ringgold ID: RIN622463)
,
Ayşegül Aksu
3   Department of Nuclear Medicine, İzmir Kâtip Çelebi University, Atatürk Training and Research Hospital, Izmir, Turkey (Ringgold ID: RIN226844)
,
Tuçe Söylemez Akkurt
2   Department of Pathology, Başakşehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey (Ringgold ID: RIN622463)
,
Burcu Esen Akkaş
1   Department of Nuclear Medicine, Başakşehir Cam and Sakura City Hospital, University of Health Sciences, Istanbul, Turkey (Ringgold ID: RIN622463)
› Author Affiliations
› Further Information
Also available at
    Permissions and Reprints

Abstract

Objective

To determine the value of radiomics data extraction from baseline 18F FDG PET/CT in the prediction of tumor-infiltrating lymphocytes (TILs) among patients with primary breast cancer (BC).

Methods

We retrospectively evaluated 74 patients who underwent baseline 18F FDG PET/CT scans for BC evaluation between October 2020 and April 2022. Radiomics data extraction resulted in a total of 131 radiomic features from primary tumors. TILs status was defined based on histological analyses of surgical specimens and patients were categorized as having low TILs or moderate & high TILs. The relationships between TILs groups and tumor features, patient characteristics and molecular subtypes were examined. Features with a correlation coefficient of less than 0.6 were analyzed by logistic regression to create a predictive model. The diagnostic performance of the model was calculated via receiver operating characteristics (ROC) analysis.

Results

Menopausal status, histological grade, nuclear grade, and four radiomics features demonstrated significant differences between the two TILs groups. Multivariable logistic regression revealed that nuclear grade and three radiomics features (Morphological COMShift, GLCM Correlation, and GLSZM Small Zone Emphasis) were independently associated with TIL grouping. The diagnostic performance analysis of the model showed an AUC of 0.864 (95% CI: 0.776–0.953; p < 0.001). The sensitivity, specificity, PPV, NPV and accuracy values of the model were 69.6%, 82.4%, 64%, 85.7% and 78.4%, respectively

Conclusion

The pathological TIL scores of BC patients can be predicted by using radiomics feature extraction from baseline 18F FDG PET/CT scans.

Keywords

18F FDG PET/CT - breast cancer - tumor-infiltrating lymphocytes - radiomics


Publication History

Received: 19 April 2024

Accepted after revision: 08 January 2025

Article published online:
28 January 2025

© 2025. Thieme. All rights reserved.

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany

 

  • References

  • 1 Torre LA, Bray F, Siegel RL. et al. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65: 87-108
    CrossrefPubMedSearch in Google Scholar
  • 2 Villegas SL, Nekljudova V, Pfarr N. et al. Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors-An analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 2021; 148: 159-170
    CrossrefPubMedSearch in Google Scholar
  • 3 Dimitrakopoulos FI, Goussia A, Koliou GA. et al. Ten-year clinical outcome, toxicity and compliance of dose-dense sequential adjuvant administration of cyclophosphamide & epirubicin followed by docetaxel in patients with early breast cancer: A hellenic cooperative oncology group observational study (HE 10/10) with concurrent investigation of significance of tumor infiltrating lymphocytes. Breast 2023; 73: 103668
    CrossrefPubMedSearch in Google Scholar
  • 4 Zheng L, Qin S, Si W. et al. Pan-cancer single-cell landscape of tumor-infiltrating T cells. Science 2021; 374: abe6474
    CrossrefPubMedSearch in Google Scholar
  • 5 Wein L, Savas P, Luen SJ. et al. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions. Front Oncol 2017; 7: 156
    CrossrefPubMedSearch in Google Scholar
  • 6 Denkert C, von Minckwitz G, Darb-Esfahani S. et al. Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy. Lancet Oncol 2018; 19: 40-50
    CrossrefPubMedSearch in Google Scholar
  • 7 Hwang HW, Jung H, Hyeon J. et al. A nomogram to predict pathologic complete response (pCR) and the value of tumor-infiltrating lymphocytes (TILs) for prediction of response to neoadjuvant chemotherapy (NAC) in breast cancer patients. Breast Cancer Res Treat 2019; 173: 255-266
    CrossrefPubMedSearch in Google Scholar
  • 8 Salgado R, Denkert C, Campbell C. et al. Tumor-infiltrating lymphocytes and associations with pathological complete response and event-free survival in HER2-positive early-stage breast cancer treated with Lapatinib and Trastuzumab: A secondary analysis of the NeoALTTO trial. ” JAMA Oncol 2015; 14: 448-454
    CrossrefPubMedSearch in Google Scholar
  • 9 Kwon HW, Lee JH, Pahk K. et al. Clustering subtypes of breast cancer by combining immunohistochemistry profiles and metabolism characteristics measured using FDG PET/CT. Cancer Imaging 2021; 21: 55
    CrossrefPubMedSearch in Google Scholar
  • 10 Staal FCR, van der Reijd DJ, Taghavi M. et al. Radiomics for the Prediction of Treatment Outcome and Survival in Patients With Colorectal Cancer: A Systematic Review. Clin Colorectal Cancer 2021; 20: 52-71
    CrossrefPubMedSearch in Google Scholar
  • 11 Stefano A, Leal A, Richiusa S. et al. Robustness of pet radiomics features: Impact of co-registration with mri. Applied Sciences 2021; 11: 10170
    CrossrefSearch in Google Scholar
  • 12 Vural Topuz Ö, Aksu A, Yılmaz Özgüven MB. A different perspective on 18F-FDG PET radiomics in colorectal cancer patients: The relationship between intra & peritumoral analysis and pathological findings. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2023; 42: 359-366
    PubMedSearch in Google Scholar
  • 13 Savas P, Salgado R, Denkert C. et al. Clinical relevance of host immunity in breast cancer: from TILs to the clinic. Nat Rev Clin Oncol 2016; 13: 228-241
    CrossrefPubMedSearch in Google Scholar
  • 14 Park S, Min EK, Bae SJ. et al. Relationship of the standard uptake value of 18F-FDG-PET-CT with tumor-infiltrating lymphocytes in breast tumors measuring ≥ 1 cm. Sci Rep 2021; 11: 12046
    CrossrefPubMedSearch in Google Scholar
  • 15 Sasada S, Shiroma N, Goda N. et al. The relationship between ring-type dedicated breast PET and immune microenvironment in early breast cancer. Breast Cancer Res Treat 2019; 177: 651-657
    CrossrefPubMedSearch in Google Scholar
  • 16 Su GH, Xiao Y, Jiang L. et al. Radiomics features for assessing tumor-infiltrating lymphocytes correlate with molecular traits of triple-negative breast cancer. J Transl Med 2022; 20: 471
    CrossrefPubMedSearch in Google Scholar
  • 17 Yu H, Meng X, Chen H. et al. “Predicting the Level of Tumor-Infiltrating Lymphocytes in Patients With Breast Cancer: Usefulness of Mammographic Radiomics Features. Front Oncol 2021; 11: 628577
    CrossrefPubMedSearch in Google Scholar
  • 18 Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 1471-1474
    CrossrefPubMedSearch in Google Scholar
  • 19 Wolff AC, Hammond MEH, Allison KH. et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol 2018; 36: 2105-2122
    CrossrefPubMedSearch in Google Scholar
  • 20 Allison KH, Hammond MEH, Dowsett M. et al. “Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol 2020; 38: 1346-1366
    CrossrefPubMedSearch in Google Scholar
  • 21 Loibl S, André F, Bachelot T. et al. “ESMO Guidelines Committee. Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†. Ann Oncol 2024; 35: 159-182
    CrossrefPubMedSearch in Google Scholar
  • 22 Hendry S, Salgado R, Gevaert T. et al. Assessing tumor-infiltrating lymphocytes in solid tumors: a practical view for pathologists and proposal for a standardized method from the International Immunooncology Biomarkers Working Group. Adv Anat Pathol 2017; 24: 311-335
    CrossrefPubMedSearch in Google Scholar
  • 23 Salgado R, Denkert C, Demaria S. et al. “The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: Recommendations by an international TILs working group 2014. Ann Oncol 2015; 26: 259-271
    CrossrefPubMedSearch in Google Scholar
  • 24 Fujimoto Y, Watanabe T, Hida AI. et al. “Prognostic significance of tumor-infiltrating lymphocytes may differ depending on Ki67 expression levels in estrogen receptor-positive/HER2-negative operated breast cancers”. Breast Cancer 2019; 26: 738-747
    CrossrefPubMedSearch in Google Scholar
  • 25 Xu N, Zhou J, He X. et al. Radiomics Model for Evaluating the Level of Tumor-Infiltrating Lymphocytes in Breast Cancer Based on Dynamic Contrast-Enhanced MRI. Clin Breast Cancer 2021; 21: 440-449
    CrossrefPubMedSearch in Google Scholar
  • 26 Boellaard R, Delgado-Bolton R, Oyen WJ. et al. European Association of Nuclear Medicine (EANM). FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 2015; 42: 328-354
    CrossrefPubMedSearch in Google Scholar
  • 27 Nioche C, Orlhac F, Boughdad S. et al. LIFEx: A Freeware for Radiomic Feature Calculation in Multimodality Imaging to Accelerate Advances in the Characterization of Tumor Heterogeneity. Cancer Res 2018; 78: 4786-4789
    CrossrefPubMedSearch in Google Scholar
  • 28 McHugh ML. Interrater reliability: the kappa statistic. Biochem Med (Zagreb) 2012; 22: 276-282
    CrossrefPubMedSearch in Google Scholar
  • 29 Liu RX, Kuang J, Gong Q. et al. Principal component regression analysis with SPSS. Comput Methods Programs Biomed 2003; 71: 141-147
    CrossrefPubMedSearch in Google Scholar
  • 30 Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nat Rev Cancer 2011; 11: 85-95
    CrossrefPubMedSearch in Google Scholar
  • 31 Özcan D, Lade-Keller J, Tramm T. Can evaluation of mismatch repair defect and TILs increase the number of triple-negative breast cancer patients eligible for immunotherapy?. Pathol Res Pract 2021; 226: 153606
    CrossrefPubMedSearch in Google Scholar
  • 32 Pujani M, Jain H, Chauhan V. et al. Evaluation of Tumor infiltrating lymphocytes in breast carcinoma and their correlation with molecular subtypes, tumor grade and stage. Breast Dis 2020; 39: 61-69
    CrossrefPubMedSearch in Google Scholar
  • 33 Hirakata T, Fujii T, Kurozumi S. et al. FDG uptake reflects breast cancer immunological features: the PD-L1 expression and degree of TILs in primary breast cancer. Breast Cancer Res Treat 2020; 18: 331-338
    CrossrefPubMedSearch in Google Scholar
  • 34 Murakami W, Tozaki M, Sasaki M. et al. Correlation between 18F-FDG uptake on PET/MRI and the level of tumor-infiltrating lymphocytes (TILs) in triple-negative and HER2-positive breast cancer. Eur J Radiol 2020; 123: 108773
    CrossrefPubMedSearch in Google Scholar
  • 35 Mori M, Passoni P, Incerti E. et al. “Training and validation of a robust PET radiomic-based index to predict distant-relapse-free-survival after radio-chemotherapy for locally advanced pancreatic cancer. Radiother Oncol 2020; 153: 258-264
    CrossrefPubMedSearch in Google Scholar
  • 36 Singh S, Srivastava D. “2017 5th International Symposium on Computational and Business Intelligence (ISCBI), Dubai, United Arab Emirates”. 2017
    Search in Google Scholar
  • 37 Lee HS, Oh JS, Park YS. et al. Differentiating the grades of thymic epithelial tumor malignancy using textural features of intratumoral heterogeneity via (18)F-FDG PET/CT. Ann Nucl Med 2016; 30: 309-319
    CrossrefPubMedSearch in Google Scholar
  • 38 Fumagalli C, Barberis M. Breast Cancer Heterogeneity. Diagnostics (Basel) 2021; 11: 1555
    CrossrefPubMedSearch in Google Scholar
  • 39 McDonald KA, Kawaguchi T, Qi Q. et al. Tumor Heterogeneity Correlates with Less mmune Response and Worse Survival in Breast Cancer Patients. Ann Surg Oncol 2019; 26: 2191-2199
    CrossrefPubMedSearch in Google Scholar
  • 40 Gao ZH, Li CX, Liu M. et al. Predictive and prognostic role of tumour-infiltrating lymphocytes in breast cancer patients with different molecular subtypes: a meta-analysis. BMC Cancer 2020; 20: 1150
    CrossrefPubMedSearch in Google Scholar
  • 41 Foster B, Bagci U, Mansoor A. et al. A review on segmentation of positron emission tomography images. Comput Biol Med 2014; 50: 76-96
    CrossrefPubMedSearch in Google Scholar
  • 42 Ha S, Choi H, Paeng JC. et al. Radiomics in Oncological PET/CT: a Methodological Overview. Nucl Med Mol Imaging 2019; 53: 14-29
    CrossrefPubMedSearch in Google Scholar